Sumitomo Pharma has completed registration for issuance of up to 60,000,000 shares with a maximum amount of 140 billion yen, planning to promote the growth strategy “Boost 2028” through fundraising.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4005","jir_company_name":"Sumitomo Chemical Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4005-20260302-01.pdf","jir_short_summary":"Sumitomo Pharma has completed registration for issuance of up to 60,000,000 shares with a maximum amount of 140 billion yen, planning to promote the growth strategy \"Boost 2028\" through fundraising.","jir_summary":"### Overview of Capital Policy\nSumitomo Pharma, a consolidated subsidiary of Sumitomo Chemical, resolved at its Board of Directors meeting on March 2, 2026 to register for new share issuance and applied for registration with the Kanto Local Finance Bureau. The number of shares to be issued is up to 60,000,000 shares, with a maximum issuance amount of 140 billion yen; specific issuance conditions and timing are undecided. The procured funds are intended for research and development, capital investment, financing and investments, working capital, and repayment of interest-bearing debt.\n\n### Impact on Shareholders and Future Outlook\nThis capital increase is expected to dilute Sumitomo Chemical\u2019s voting rights ratio in Sumitomo Pharma, but there will be no change to its status as a consolidated subsidiary. Additionally, Sumitomo Chemical is considering refinancing borrowings without debt guarantees from Sumitomo Chemical, aiming to replace existing borrowings. These measures will strengthen the financial foundation, accelerate the execution of the growth strategy \"Boost 2028,\" and aim to enhance corporate value over the medium to long term.","jir_financial_highlights":"Number of Shares to be Issued: 60,000,000 shares (maximum) (Unknown)\nPlanned Issuance Amount: 140 billion yen (maximum) (Unknown)\nPlanned Issuance Period: From March 10, 2026 to March 9, 2027 (Unknown)","jir_category":"","jir_hashtags":"#SumitomoChemical, #CapitalPolicy, #NewShareIssuance, #JapaneseStocks","jir_key_figures":"Number of Shares to be Issued: 60,000,000 shares (maximum)\nPlanned Issuance Amount: 140 billion yen (maximum)\nPlanned Issuance Period: From March 10, 2026 to March 9, 2027","jir_meta_title":"Sumitomo Pharma Registers for New Share Issuance up to 60,000,000 Shares and 140 Billion Yen","jir_meta_description":"Sumitomo Pharma, a subsidiary of Sumitomo Chemical, has registered for new share issuance of up to 60,000,000 shares totaling 140 billion yen to strengthen its financial base and invest in growth, advancing its Boost 2028 growth strategy.","jir_og_title":"Sumitomo Pharma Announces Registration for New Share Issuance to Raise up to 140 Billion Yen","jir_og_description":"Sumitomo Pharma, a subsidiary of Sumitomo Chemical, has registered for new share issuance of up to 60,000,000 shares with a maximum value of 140 billion yen, accelerating its Boost 2028 growth strategy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7702,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-32738","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n